Glecaprevir/Pibrentasvir in People with Hepatitis C During Pregnancy

Ahizechukwu Eke, MD PhD
Associate Professor of Maternal Fetal Medicine
Johns Hopkins University School of Medicine,
Baltimore, Maryland.
ACOG Hepatitis C Screening Recommendations

Routine Hepatitis C Virus Screening in Pregnant Individuals

Practice Advisory
May 2021

Brenna L. Hughes, Denise Jamieson, Anjali J. Kaimal, Aaron B Caughey, Ahizechukwu Eke, Megan Reynolds.
ACOG Hepatitis C Screening Recommendations

• Recommends screening for all pregnant individuals during each pregnancy

• Currently no HCV approved therapy for use during pregnancy

• Screening identifies patients to start direct antiviral agents postpartum

• Promotes dialogue between OBGYN, Pediatricians, Hepatologists, GI
Direct Antiviral Agents During Pregnancy

**Direct antiviral agents (DAAs) and their use in pregnant women with hepatitis C (HCV)**

Sandra Abdul Massih¹, Ahizechukwu C. Eke¹,²  
¹Division of Clinical Pharmacology & Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, 1800 Orleans Street, Baltimore, MD 21287.  
²Division of Maternal Fetal Medicine, Department of Gynecology & Obstetrics, Johns Hopkins University School of Medicine, 600 N Wolfe Street, Phipps 228, Baltimore, MD 21287.

**Abstract**

**Introduction:** Direct-Acting Antiviral Agents (DAAs) provide safer, efficacious, tolerable,
IMPAACT 2041 – Phase 1/II of GLE/PIB

IMPAACT 2041
Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir in People with Hepatitis C During Pregnancy

PRIMARY PROTOCOL TEAM MEMBERS

Ahizechukwu Eke
STUDY CHAIR

Nathan Furukawa
STUDY VICE-CHAIR

Renee Browning
DAIDS MEDICAL OFFICER

Christine Chiou
DAIDS MEDICAL OFFICER

Frankiin Yates
NICHID MEDICAL OFFICER

Sonia Lee
NICHID MEDICAL OFFICER
IMPAACT 2041 – Phase 1/II of GLE/PIB

- NIAID/NICHD – IMPAACT funded study
- Protocol writing phase
- Plan on recruiting 30 evaluable pregnant persons with HCV
  - 20 with HCV
  - 10 with HCV and HIV
- Eight weeks of therapy
  - Pharmacokinetics
  - Safety and efficacy
- Recruitment likely to open in October 2023